Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

Revolution Medicines' stock has surged over 150% this year following FDA approval of Rasonque, its pancreatic cancer drug that nearly doubled survival rates. The company's RAS-inhibitor platform has de-risked the biological mechanism with multiple phase 3 trials underway. However, the company remains unprofitable with Q3 losses of $407.5 million despite $198 million in revenue from five weeks of Rasonque sales. Analyst price targets suggest significant upside potential.